1,2,3,4,6-Penta-O-galloyl-β-D-glucose Inhibits CD44v3, a cancer stem cell marker, by regulating its transcription factor, in human pancreatic cancer cell line

References

• Bae MS, Kim EY, Kim YH. 2019. Anti-pancreatic cancer effect of 1,2,3,4,6-penta-O-galloyl-b-D-glucose in PANC-1 through inhibition of CD44. J Korean Soc Food Sci Nutr. 48:1440–1446.
   Google Scholar
• Barati M, Akhondi M, Mousavi NS, Haghparast N, Ghodsi A, Baharvand H, Ebrahimi M, Hassani SN. 2021. Pluripotent stem cells: cancer study, therapy, and vaccination. Stem Cell Rev Rep. 17:1975–1332.
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Wong G, Earle C, Chen L. 2012. Hyaluronan-CD44v3 interaction with Oct4-Sox2- Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 287:32800–32824.
   PubMed Web of Science ®Google Scholar
• Cancer.Net®. 2022. Pancreatic Cancer: Statistics. https://www.cancer.net/cancer-types/pancreatic-cancer/statistics#:~:text = The%20general%205-year (accessed February 2022).
   Google Scholar
• Chai Y, Lee HJ, Shaik AA, Nkhata K, Xing C, Zhang J, Jeong SJ, Kim SH, Lu J. 2010. Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negative xenograft growth. Breast Cancer Res. 12:R67.
   PubMed Web of Science ®Google Scholar
• Chang CH, Pauklin S. 2021. Extracellular vesicles in pancreatic cancer progression and therapies. Cell Death Dis. 12:973–992.
   PubMed Web of Science ®Google Scholar
• Chaudhry GES, Akim A, Zafar MN, Safdar N, Sung YY, Muhammad TST. 2021. Understanding hyaluronan receptor (CD44) interaction, HA-CD44 activated potential targets in cancer therapeutics. Adv Pharm Bull. 11:426–438.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhao S, Karnad A, Freeman JW. 2018. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 11:64–87.
   PubMed Web of Science ®Google Scholar
• Chen K, Zhang C, Ling S, Wei R, Wang J, Xu X. 2021. The metabolic flexibility of quiescent CSC: implications for chemotherapy. Cell Death Dis. 12:835.
   PubMed Web of Science ®Google Scholar
• Claudia DC, Jessica B, Cecconi D. 2018. Pancreatic cancer stem cells: perspectives on potential therapeutic approaches of pancreatic ductal adenocarcinoma. World J Stem Cells. 10:172–182.
   PubMed Web of Science ®Google Scholar
• Franken AP, Rodermond HM, Jan S, Jaap H, Bree CV. 2006. Clonogenic assay of cells in vitro. Natureprotocols. 1:2315–2319.
   PubMed Web of Science ®Google Scholar
• Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, et al. 2008. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell. 134:62–73.
   PubMed Web of Science ®Google Scholar
• Gotte M, Yip GW. 2006. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 66:10233–10237.
   PubMed Web of Science ®Google Scholar
• Gregory S, Hugo V, Lies G, Baki T. 2009. Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nature. 6:580–586.
   Web of Science ®Google Scholar
• Guo Q, Yang C, Gao F. 2021. The state of CD44 activation in cancer progression and therapeutic targeting. FEBS J. Online ahead of print. doi:10.1111/febs.16179.
   Web of Science ®Google Scholar
• Gzil A, Zarębska I, Bursiewicz W, Antosik P, Grzanka D, Szylberg Ł. 2019. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Mol Biol Rep. 46:6629–6645.
   PubMed Web of Science ®Google Scholar
• Hong SP, Jing W, Bang SM, Park SW, Song SY. 2009. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 125:2323–2331.
   PubMed Web of Science ®Google Scholar
• Hu H, Lee HJ, Jiang C, Zhang J, Wang L, Zhao Y, Xiang Q, Lee EO, Kim SH, Lü J. 2008. Penta-1,2,3,4,6-O-galloyl-beta-D-glucose induces p53 and inhibits STAT3 in prostate cancer cells in vitro and suppresses prostate xenograft tumor growth in vivo. Mol Cancer Ther. 7:2681–2691.
   PubMed Web of Science ®Google Scholar
• Ishiwata T, Matsuda Y, Yoshimura H, Sasaki N, Ishiwata S, Ishikawaet N, Takubo K, Arai T, Aida J. 2018. Pancreatic cancer stem cells: features and detection methods. Pathol Oncol Res. 24:797–805.
   PubMed Web of Science ®Google Scholar
• Jang SE, Hyam SR, Jeong JJ, Han MJ, Kim DH. 2013. Penta-O-galloyl-beta-D-glucose ameliorates inflammation by inhibiting MyD88/NF-κB and MyD88/MAPK signalling pathways. Br J Pharmacol. 170:1078–1091.
   PubMed Web of Science ®Google Scholar
• Janiszewska M, Primi MC, Izard T. 2020. Cell adhesion in cancer: beyond the migration of single cells. J Biol Chem. 295:2495–2505.
   PubMed Web of Science ®Google Scholar
• Kawk SH, Kang YR, Kim YH. 2018. 1,2,3,4,6-Penta-O-galloyl-β-d-glucose suppresses colon cancer through induction of tumor suppressor. Bioorg Med Chem Lett. 28:2117–2123.
   PubMed Web of Science ®Google Scholar
• Kim BH, Choi MS, Lee HG, Lee SH, Noh KH, Sunho K, Jeong AJ, Haeri L, Yi EH, Park JY, et al. 2015. Photoprotective potential of penta-O-galloyl-beta-D glucose by targeting NF-kappaB and MAPK signaling in UVB radiation-induced human dermal fibroblasts and mouse skin. Mol Cells. 38:982–990.
   PubMed Web of Science ®Google Scholar
• Kumazoe M, Takai M, Bae J, Hiroi S, Huang Y, Takamatsu K, Won Y, Yamashita M, Hidaka S, Yamashita S, et al. 2016. FOXO3 is essential for CD44 expression in pancreatic cancer cells. Oncogene. 36:2643–2654.
   PubMed Web of Science ®Google Scholar
• Kuniyasu H, Chihara Y, Kubozoe T, Takahashi T. 2002. Co-expression of CD44v3 and Heparanase is correlated with metastasis of human colon cancer. Int J Mol Med. 10:333–337.
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Bae JS, Lee HY, Hwang JY, Lee EW, Ito H, Kim TH. 2013. Pancreatic lipase inhibitory gallotannins from galla rhois with inhibitory effects on adipocyte differentiation in 3T3-L1 cells. Molecules. 18:10629–10638.
   PubMed Web of Science ®Google Scholar
• Lee HW, Kang YR, Bae MS, Kim YH. 2017. Anti-inflammatory effects of 1,2,3,4,6-penta-O-galloyl-b-D-glucose in LPS-stimulated macrophages. J Korean Soc Food Sci Nutr. 46:409–416.
   Google Scholar
• Lee JE, Lim YH, Kim JH. 2021. UCH-1 and UCH-L3 regulate the cancer stem cell-like properties through PI3K/Akt signaling pathway in prostate cancer cells. Anim Cells Syst (Seoul). 25(5):312–322.
   PubMed Web of Science ®Google Scholar
• Li L, Hao X, Qin J, Tang W, He F, Smith A, Zhang M, Simeone DM, Qiao XT, Chen ZN, et al. 2014. Antibody against CD44s inhibits pancreatic tumor initiation and post-radiation recurrence in mice. Gastroenterol. 146:1108–1118.
   PubMed Web of Science ®Google Scholar
• Lindenboim L, Zohar H, Worman HJ, Stein R. 2020. The nuclear envelope: target and mediator of the apoptotic process. Cell Death Discov. 6:29.
   PubMed Web of Science ®Google Scholar
• Mendonca P, Alghamdi S, Messeha S, Soliman KFA. 2021. Pentagalloyl glucose inhibits TNF-α-activated CXCL1/GRO-α expression and induces apoptosis-related genes in triple-negative breast cancer cells. Sci Rep. 11:5649–5662.
   PubMed Web of Science ®Google Scholar
• Palamaris K, Felekouras E, Sakellariou S. 2021. Epithelial to mesenchymal transition: key regulator of pancreatic ductal adenocarcinoma progression and chemoresistance. Cancers (Basel). 13:5532.
   PubMed Web of Science ®Google Scholar
• Patil K, Khan FB, Akhtar S, Ahmad A, Uddin S. 2021. The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance. Cancer Metastasis Rev. 40:691–720.
   PubMed Web of Science ®Google Scholar
• Pook H, Pauklin S. 2021. Mechanisms of cancer cell death: therapeutic implications for pancreatic ductal adenocarcinoma. Cancers (Basel). 13:4834.
   PubMed Web of Science ®Google Scholar
• Preeti S, Dominic A, Rao RS, Shankargoude P, Awan KH, Sowmya SV, Haragannavar VC, Kacitha P. 2021. Role of cancer stem cells in head-and-neck squamous cell carcinoma - a systematic review. J Carcinog. 20:12.
   PubMedGoogle Scholar
• Reategui EP, Mayolo AA, Das PM, Astor FC, Singal R, Hamiltor KL, Goodwin WJ, Carraway KL, Franzmann EJ. 2006. Characterization of CD44v3 containing isoforms in head and neck cancer. Cancer Biol Ther. 5:1163–1168.
   PubMed Web of Science ®Google Scholar
• Robinson M, Gilbert SF, Waters JA, Lujano-Olazaba O, Lara J, Alexander LJ, Green SE, Burkeen GA, Patrus O, Sarwar Z, et al. 2021. Characterization of Sox2, Oct4 and NANOG in ovarian cancer tumor-initiating cells. Cancers (Basel). 13:262.
   PubMedGoogle Scholar
• Shayimu P, Yusufu A, Rehemutula A, Redati D, Jiapaer R, Tuerdi R. 2021. MTBP promoted the proliferation, migration and invasion of colon cancer cells by activation the expression of ZEB2. Anim Cells Syst (Seoul). 25(3):152–160.
   PubMed Web of Science ®Google Scholar
• Smith SM, Lyu YL, Cai L. 2014. NF-κB affects proliferation and invasiveness of breast cancer cells by regulating CD44 expression. PLoS One. 9:e106966. 1-9.
   PubMed Web of Science ®Google Scholar
• Tang Z, Xu Z, Zhu X, Zhang J. 2021. New insights into molecules and pathways of cancer metabolism and therapeutic implications. Cancer Commun(Lond). 41:16–36.
   PubMed Web of Science ®Google Scholar
• To WS, Midwood KS. 2011. Plasma and cellular Fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair. 4:4–21.
   PubMedGoogle Scholar
• Todoroki K, Ogasawara S, Akiba J, Nakayama M, Naito Y, Seki N, Kusukawa J, Yano H. 2016. CD44v3+/CD24- cells possess cancer stem cell-like properties in human oral squamous cell carcinoma. IJCO. 48:99–109.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Wreesmann VB, Bourguignon LW. 2007. Association of CD44V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck. 29:550–558.
   PubMed Web of Science ®Google Scholar
• Wei CY, Zhu MX, Yang YW, Zhang PF, Xuan Y, Rui P, Chao G, Lu JC, Lu W, Deng XY, et al. 2019. Downregulation of RNF128 activates Wnt/b-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J Hematol Oncol. 12:21.
   PubMed Web of Science ®Google Scholar
• Wood NJ. 2014. Pancreatic cancer: pancreatic tumour formation and recurrence after radiotherapy are blocked by targeting CD44. Nat Rev Gastro Hepat. 11:73.
   PubMedGoogle Scholar
• Zhao S, Chen C, Chang K, Karnad A, Jagirdar J, Kumar AP, Freeman JW. 2016. CD44 expression level and isoform contributes to pancreatic cancer cell plasticity, invasiveness, and response to therapy. Clin Cancer Res. 22:5592–5604.
   PubMed Web of Science ®Google Scholar